By and large, SGLT2i successfully reduces the amount of Na+ entering cells by inhibiting NHE1 and improves the contractile dysfunction in heart failure by normalizing the intracellular pH, thereby producing cardiovascular benefits. The gene discussed is SLC9A1; the disease is heart failure.